{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:27:42Z","timestamp":1787682462458,"version":"build-2784847793"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T00:00:00Z","timestamp":1564185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T00:00:00Z","timestamp":1564185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12981-019-0230-6","type":"journal-article","created":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T08:02:48Z","timestamp":1564214568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir"],"prefix":"10.1186","volume":"16","author":[{"given":"Laura","family":"Campogiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Cerva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Maffongelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Teti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Pupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Vaccarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cantonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pennica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1452-0333","authenticated-orcid":false,"given":"Loredana","family":"Sarmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,27]]},"reference":[{"key":"230_CR1","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.2147\/OTT.S167392","volume":"11","author":"Mayur Narkhede","year":"2018","unstructured":"Narkhede Mayur, Arora Shagun, Ujjani Chaitra. Primary effusion lymphoma: current perspectives. Onco Targets Ther. 2018;11:3747\u201354.","journal-title":"Onco Targets Ther."},{"key":"230_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4132\/KoreanJPathol.2014.48.2.81","volume":"48","author":"Y Kim","year":"2014","unstructured":"Kim Y, Park CJ, Roh J, Huh J. Current concepts in primary effusion lymphoma and other effusion-based lymphomas. Korean J Pathol. 2014;48:81\u201390.","journal-title":"Korean J Pathol."},{"key":"230_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1128\/CMR.15.3.439-464.2002","volume":"15","author":"DV Ablashi","year":"2002","unstructured":"Ablashi DV, Chatlynne LG, Whitman JE Jr., Cesarman E. Spectrum of Kaposi\u2019s sarcoma-associated Herpesvirus, or Human Herpesvirus 8, diseases. Clin Microbiol Rev. 2002;15:439\u201364.","journal-title":"Clin Microbiol Rev."},{"issue":"5192","key":"230_CR4","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1126\/science.7997879","volume":"266","author":"Y Chang","year":"1994","unstructured":"Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi\u2019s sarcoma. Science. 1994;266(5192):1865\u20139.","journal-title":"Science"},{"issue":"18","key":"230_CR5","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","volume":"332","author":"E Cesarman","year":"1995","unstructured":"Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi\u2019s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332(18):1186\u201391.","journal-title":"N Engl J Med"},{"issue":"1","key":"230_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1053\/paor.1999.0073","volume":"5","author":"G Mikala","year":"1999","unstructured":"Mikala G, Xie J, Berencsi G, Kiss C, M\u00e1rton I, Domj\u00e1n G, V\u00e1lyi-Nagy I. Human herpesvirus 8 in hematologic diseases. Pathol Oncol Res. 1999;5(1):73\u20139.","journal-title":"Pathol Oncol Res."},{"issue":"19","key":"230_CR7","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The\u00a02008\u00a0WHO\u00a0classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019\u201332.","journal-title":"Blood"},{"issue":"2","key":"230_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/ajh.24251","volume":"91","author":"S Guillet","year":"2016","unstructured":"Guillet S, Gerard L, Meignin V, Agbalika F, Cuccini W, Denis B, Katlama C, Galicier L, Oksenhendler E. Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution. Am J Hematol. 2016;91(2):233\u20137.","journal-title":"Am J Hematol"},{"issue":"21","key":"230_CR9","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1200\/JCO.2003.06.013","volume":"21","author":"C Simonelli","year":"2003","unstructured":"Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A, Vaccher E, Carbone A, Tirelli U. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol. 2003;21(21):3948\u201354.","journal-title":"J Clin Oncol."},{"issue":"5","key":"230_CR10","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3816\/CLM.2008.n.042","volume":"8","author":"T Siddiqi","year":"2008","unstructured":"Siddiqi T, Joyce RM. A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab. Clin Lymphoma Myeloma. 2008;8(5):300\u20134.","journal-title":"Clin Lymphoma Myeloma."},{"issue":"5","key":"230_CR11","first-page":"367","volume":"8","author":"S Stingaciu","year":"2010","unstructured":"Stingaciu S, Ticchioni M, Sudaka I, Haudebourg J, Mounier N. Intracavitary cidofovir for human herpes virus-8-associated primary lymphoma in an HIV-negative patient. Clin Adv Hematol Oncol. 2010;8(5):367\u201374.","journal-title":"Clin Adv Hematol Oncol."},{"key":"230_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4103\/1742-6413.56361","volume":"6","author":"F Brimo","year":"2009","unstructured":"Brimo F, Popradi G, Michel RP, Auger M. Primary efussion lymphoma involving three body cavities. Cytojournal. 2009;6:21.","journal-title":"Cytojournal."},{"issue":"11","key":"230_CR13","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1097\/01.aids.0000237381.92303.61","volume":"220","author":"NF Crum-Cianflone","year":"2006","unstructured":"Crum-Cianflone NF, Wallace MR, Looney D. Successful secondary prophylasis for primary effusion lymphoma with human herpesvirus therapy. AIDS. 2006;220(11):1567\u20139.","journal-title":"AIDS."},{"issue":"12","key":"230_CR14","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1093\/annonc\/mdl139","volume":"17","author":"TR Halfdanarson","year":"2006","unstructured":"Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M. A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol. 2006;17(12):1849\u201350.","journal-title":"Ann Oncol."},{"issue":"2","key":"230_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/00002030-200101260-00023","volume":"15","author":"L Hocqueloux","year":"2001","unstructured":"Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS. 2001;15(2):280\u20132.","journal-title":"AIDS."},{"issue":"3","key":"230_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/sj.leu.2403646","volume":"19","author":"M Luppi","year":"2005","unstructured":"Luppi M, Trovato R, Barozzi P, Vallisa D, Rossi G, Ravazzini L, Potenza L, Riva G, Morselli M, Longo G, Cavanna L, Roncaglia R, Torelli G. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia. 2005;19(3):473\u20136.","journal-title":"Leukemia"},{"issue":"4","key":"230_CR17","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1046\/j.1365-2141.2000.02478.x","volume":"111","author":"RD Pastore","year":"2000","unstructured":"Pastore RD, Chadburn A, Kripas C, Schattner EJ. Novel association of haemophagocytic s\u00edndrome with Kaposi\u00b4s sarcoma-associated herpesvirus-related primary effusion lymphoma. Br J Haematol. 2000;111(4):1112\u20135.","journal-title":"Br J Haematol"},{"issue":"5","key":"230_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/ejh.12174","volume":"91","author":"M Ozbalak","year":"2013","unstructured":"Ozbalak M, Tokatli I, \u00d6zdemiri M, Tecimer T, Ar MC, \u00d6rnek S, Koroglu A, Laleli Y, Ferhanoglu B. Is valganciclovir really effective in primary effusion lymphoma: case report of an HIV (\u2212) EBV (\u2212) HHV8 (+) patient. Eur J Haematol. 2013;91(5):467\u20139.","journal-title":"Eur J Haematol"},{"issue":"4","key":"230_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/MCP.0000000000000384","volume":"23","author":"N Arora","year":"2017","unstructured":"Arora N, Gupta A, Sadeghi N. Primary effusion lymphoma: current concepts and management. Curr Opin Pulm Med. 2017;23(4):365\u201370.","journal-title":"Curr Opin Pulm Med."},{"key":"230_CR20","doi-asserted-by":"publisher","first-page":"bcr2014204533","DOI":"10.1136\/bcr-2014-204533","volume":"2014","author":"R Pereira","year":"2014","unstructured":"Pereira R, Carvalho J, Patr\u00edcio C, Farinha P. Sustained complete remission of primary effusion lymphoma with adjunctive ganciclovir treatment in an HIV-positive patient. BMJ Case Rep. 2014;2014:bcr2014204533.","journal-title":"BMJ Case Rep."},{"issue":"1","key":"230_CR21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/hon.2445","volume":"36","author":"J Marquet","year":"2018","unstructured":"Marquet J, Velazquez-Kennedy K, L\u00f3pez S, Benito A, Blanchard MJ, Garcia-Vela JA. Case report of a primary effusion lymphoma successfully treated with oral valganciclovir after failing chemotherapy. Hematol Oncol. 2018;36(1):316\u20139.","journal-title":"Hematol Oncol"},{"key":"230_CR22","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/ajh.21108","volume":"83","author":"A Bestawros","year":"2008","unstructured":"Bestawros A. Multicentric Castleman\u2019s disease treated with combination chemotherapy and rituximab in four HIV positive men: a case series. Am J Hematol. 2008;83:508\u201311.","journal-title":"Am J Hematol."},{"issue":"6","key":"230_CR23","doi-asserted-by":"publisher","first-page":"e592","DOI":"10.3747\/co.25.4119","volume":"25","author":"J Chen","year":"2018","unstructured":"Chen J, Mehraj V, Szabo J, Routy B, Michel RP, Routy JP. Multiple remissions of extracavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patient infected with HIV. Curr Oncol. 2018;25(6):e592\u20136.","journal-title":"Curr Oncol."},{"key":"230_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jcv.2008.01.016","volume":"42","author":"A Bestawros","year":"2008","unstructured":"Bestawros A, Boulassel MR, Michel RP, Routy JP. HHV-8 linked to Kaposi\u2019s sarcoma, Castleman\u2019s disease and primary effusion lymphoma in a hiv1-infected man. J Clin Virol. 2008;42:179\u201381.","journal-title":"J Clin Virol"},{"issue":"11","key":"230_CR25","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1097\/01.pas.0000138177.10829.5c","volume":"28","author":"A Chadburn","year":"2004","unstructured":"Chadburn A, Hyjek E, Mathew S, Cesarman E, Said J, Knowles DM. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol. 2004;28(11):1401\u201316.","journal-title":"Am J Surg Pathol"},{"key":"230_CR26","unstructured":"Steven H, Swerdlow E, Campo MD, Nancy L, Harris MD, Elaine S, Jaffe D, editor. WHO Classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 260\u2013261."},{"issue":"6","key":"230_CR27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/PAS.0000000000000823","volume":"41","author":"T Bhavsar","year":"2017","unstructured":"Bhavsar T, Lee JC, Perner Y, Raffeld M, Xi L, Pittaluga S, Jaffe ES. KSHV- and EBV-associated germinotropic lymphoproliferative disorder: new findings and review of the literature. Am J Surg Pathol. 2017;41(6):795\u2013800.","journal-title":"Am J Surg Pathol."},{"key":"230_CR28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2141.2007.06879.x","volume":"140","author":"A Carbone","year":"2008","unstructured":"Carbone A, Gloghini A. KSHV\/HHV8-associated lymphomas. Br J Haematol. 2008;140:13\u201324.","journal-title":"Br J Haematol"},{"key":"230_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/cncr.22691","volume":"111","author":"F Brimo","year":"2007","unstructured":"Brimo F, Michel RP, Khetani K, Auger M. Primary effusion lymphoma: a series of 4 cases and review of literature with emphasis on cytomorphologic and immunocytochemical differential diagnosis. Cancer. 2007;111:224\u201333.","journal-title":"Cancer."},{"issue":"2","key":"230_CR30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ajcp\/aqw218","volume":"147","author":"A Chadburn","year":"2017","unstructured":"Chadburn A, Said J, Gratzinger D, Chan JK, de Jong D, Jaffe ES, Natkunam Y, Goodlad JR. HHV8\/KSHV-positive lymphoproliferative disorders and the spectrum of plasmablastic and plasma cell neoplasms: 2015 SH\/EAHP Workshop Report-Part 3. Am J Clin Pathol. 2017;147(2):171\u201387.","journal-title":"Am J Clin Pathol"},{"key":"230_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12308-012-0148-6","volume":"5","author":"F Fend","year":"2012","unstructured":"Fend F, Cabecadas J, Gaulard P, Jaffe ES, Kluin P, Kuzu I, Peterson LA, Wotherspoon A, Sundstr\u00f6m C. Early lesion in lymphoid neoplasia. J Hematopathol. 2012;5:169\u201399.","journal-title":"J Hematopathol."},{"issue":"14","key":"230_CR32","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1097\/QAD.0000000000001567","volume":"31","author":"PH Gon\u00e7alves","year":"2017","unstructured":"Gon\u00e7alves PH, Uldrick TS, Yarchoan R. HIV-associated Kaposi sarcoma and related diseases. AIDS. 2017;31(14):1903\u201316.","journal-title":"AIDS."},{"key":"230_CR33","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/0140-6736(91)92513-2","volume":"337","author":"V Beral","year":"1991","unstructured":"Beral V, Peterman T, Berkelman R, Jaffe H. AIDS associated non-Hodgkin lymphoma. Lancet. 1991;337:805\u20139.","journal-title":"Lancet"},{"issue":"8","key":"230_CR34","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1097\/PAS.0b013e31825b38ec","volume":"36","author":"ZG Pan","year":"2012","unstructured":"Pan ZG, Zhang QY, Lu ZB, Quinto T, Rozenvald IB, Liu LT, Wilson D, Reddy V, Huang Q, Wang HY, Ren YS. Extracavitary KSHV-associated large B cell lymphoma: a distinct entity or a subtype of primary effusion lymphoma? Study of 9 cases and review of an additional 43 cases. Am J Surg Pathol. 2012;36(8):1129\u201340.","journal-title":"Am J Surg Pathol"},{"issue":"19","key":"230_CR35","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1200\/JCO.2005.07.084","volume":"23","author":"E Boulanger","year":"2005","unstructured":"Boulanger E, G\u00e9rard L, Gabarre J, Molina JM, Rapp C, Abino JF, Cadranel J, Chevret S, Oksenhendler E. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol. 2005;23(19):4372\u201380.","journal-title":"J Clin Oncol"},{"issue":"6","key":"230_CR36","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1080\/10428194.2017.1387912","volume":"59","author":"L Qunaj","year":"2018","unstructured":"Qunaj L, Castillo JJ, Olszewski AJ. Survival of patients with CD20-negative variants of large B cell lymphoma: an analysis of the National Cancer Data Base. Leuk Lymphoma. 2018;59(6):1375\u201383.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"230_CR37","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/(SICI)1096-8652(199803)57:3<266::AID-AJH25>3.0.CO;2-7","volume":"57","author":"E Oksenhendler","year":"1998","unstructured":"Oksenhendler E, Clauvel JP, Jouveshomme S, Davi F, Mansour G. Complete remission of a primary effusion lymphoma with antiretroviral therapy. Am J Hematol. 1998;57(3):266.","journal-title":"Am J Hematol"},{"issue":"7","key":"230_CR38","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1086\/428615","volume":"40","author":"C Simonelli","year":"2005","unstructured":"Simonelli C, Tedeschi R, Gloghini A, Bortolin MT, Spina M, Bidoli E, Cinelli R, De Paoli P, Carbone A, Tirelli U. Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy. Clin Infect Dis. 2005;40(7):1022\u20137.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"230_CR39","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1172\/JCI119380","volume":"99","author":"DH Kedes","year":"1997","unstructured":"Kedes DH, Ganem D. Sensitivity of Kaposi\u2019s sarcoma-associated herpesvirus replication to antiviral drugs. Implic Potential Ther. J Clin Invest. 1997;99(9):2082\u20136.","journal-title":"Implic Potential Ther. J Clin Invest."},{"issue":"8","key":"230_CR40","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1128\/JCM.41.8.3897-3900.2003","volume":"41","author":"Y Sergerie","year":"2003","unstructured":"Sergerie Y, Boivin G. Evaluation of susceptibility of human herpesvirus 8 to antiviral drugs by quantitative real-time PCR. J Clin Microbiol. 2003;41(8):3897\u2013900.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"230_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1086\/588820","volume":"198","author":"C Casper","year":"2008","unstructured":"Casper C, Krantz EM, Corey L, Kuntz SR, Wang J, Selke S, Hamilton S, Huang ML, Wald A. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. Infect Dis. 2008;198(1):23\u201330.","journal-title":"Infect Dis."},{"issue":"Suppl 1","key":"230_CR42","first-page":"S31","volume":"21","author":"CS Rabkin","year":"1999","unstructured":"Rabkin CS, Testa MA, Huang J, Von Roenn JH. Kaposi\u2019s sarcoma and non-Hodgkin\u2019s lymphoma incidence trends in AIDS Clinical Trial Group study participants. J Acquir Immune Defic Syndr. 1999;21(Suppl 1):S31\u20133.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"230_CR43","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1097\/00002030-200005260-00010","volume":"14","author":"C Dupont","year":"2000","unstructured":"Dupont C, Vasseur E, Beauchet A, Aegerter P, Berth\u00e9 H, de Turchis P, Zucman D, Rouveix E, Saiag P. Long-term efficacy on Kaposi\u2019s sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d\u2019information et de soins de l\u2019immunodeficience humaine. AIDS. 2000;14:987\u201393.","journal-title":"AIDS."},{"key":"230_CR44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1136\/bmj.319.7201.23","volume":"319","author":"B Ledergerber","year":"1999","unstructured":"Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi\u2019s sarcoma and non-Hodgkin\u2019s lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. BMJ. 1999;319:23\u20134.","journal-title":"BMJ"},{"key":"230_CR45","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/QAD.0b013e3282f2705d","volume":"22","author":"J Polesel","year":"2008","unstructured":"Polesel J, Clifford GM, Rickenbachc M, Dal Maso L, Battegayd M, Bouchardy C, Furrerf H, Hasseg B, Levi F, Probst-Henschj NB, Schmid P, Franceschin S, the Swiss HIV Cohort Study. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS. 2008;22:301\u20136.","journal-title":"AIDS."},{"issue":"10","key":"230_CR46","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1097\/QAD.0b013e3282fc732b","volume":"22","author":"D Ripamont","year":"2008","unstructured":"Ripamont D, Marini B, Rambaldi A, Suter F. Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infection. AIDS. 2008;22(10):1236\u20137.","journal-title":"AIDS."},{"key":"230_CR47","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jcv.2015.11.037","volume":"74","author":"FR Simonetti","year":"2016","unstructured":"Simonetti FR, Ricaboni D, Cattaneo D, Micheli V, Rusconi S, Gervasoni C. Relapse of Kaposi\u2019s Sarcoma and HHV-8 viremia in an HIV-infected patient switching from protease inhibitor to integrase inhibitor-based antiretroviral therapy. J Clin Virol. 2016;74:75\u20137.","journal-title":"J Clin Virol"},{"issue":"9","key":"230_CR48","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1086\/592298","volume":"47","author":"Ryan J Sullivan","year":"2008","unstructured":"Sullivan Ryan J, Pantanowitz Liron, Casper Corey, Stebbing Justin, Dezube Bruce J. Epidemiology, pathophysiology and treatment of Kaposi sarcoma-associated herpesvirus disease: kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis. 2008;47(9):1209\u201315.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"230_CR49","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1172\/JCI40567","volume":"120","author":"D Ganem","year":"2010","unstructured":"Ganem D. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest. 2010;120(4):939\u201349.","journal-title":"J Clin Invest."},{"issue":"11","key":"230_CR50","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1158\/1535-7163.MCT-17-0041","volume":"16","author":"F Zhou","year":"2017","unstructured":"Zhou F, Shimoda M, Olney L, Lyu Y, Tran K, Jiang G, Nakano K, Davis RR, Tepper CG, Maverakis E, Campbell M, Li Y, Dandekar S, Izumiya Y. Oncolytic reactivation of KSHV as a therapeutic approach for primary effusion lymphoma. Mol Cancer Ther. 2017;16(11):2627\u201338.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"230_CR51","doi-asserted-by":"publisher","first-page":"e1006628","DOI":"10.1371\/journal.ppat.1006628","volume":"13","author":"P Shrestha","year":"2017","unstructured":"Shrestha P, Davis DA, Veeranna RP, Carey RF, Viollet C, Yarchoan R. Hypoxia-inducible factor-1 alpha as a therapeutic target for primary effusion lymphoma. PLoS Pathog. 2017;13(9):e1006628.","journal-title":"PLoS Pathog"},{"issue":"30","key":"230_CR52","doi-asserted-by":"crossref","first-page":"30408","DOI":"10.18632\/oncotarget.4655","volume":"6","author":"F Van Rhee","year":"2015","unstructured":"Van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget. 2015;6(30):30408\u201319.","journal-title":"Oncotarget."},{"issue":"7","key":"230_CR53","first-page":"1288","volume":"20","author":"P De Paoli","year":"2016","unstructured":"De Paoli P, Carbone A. Kaposi\u2019s Sarcoma Herpesvirus: twenty years after its discovery. Eur Rev Med Pharmacol Sci. 2016;20(7):1288\u201394.","journal-title":"Eur Rev Med Pharmacol Sci."},{"issue":"7","key":"230_CR54","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMc1806295","volume":"379","author":"NN Shah","year":"2018","unstructured":"Shah NN, Singavi AK, Harrington A. Daratumumab in primary effusion lymphoma. N Engl J Med. 2018;379(7):689\u201390.","journal-title":"N Engl J Med"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-019-0230-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12981-019-0230-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-019-0230-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T12:05:31Z","timestamp":1721563531000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-019-0230-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,27]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["230"],"URL":"https:\/\/doi.org\/10.1186\/s12981-019-0230-6","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,27]]},"assertion":[{"value":"16 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Signed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Pennica Alfredo\u2014Participation in conferences organized by MSD and Gilead. Massimo Andreoni has received speaker fees, travel grants, and consulting fees from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, ViiV Healthcare, and Janssen-Cilag. Loredana Sarmati has received travel grants from Gilead Sciences and Merck Sharp & Dohme, payment for lectures from Gilead Sciences, Merck Sharp & Dohme and Abbvie. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}